Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/0008-5472.CAN-15-2974 http://scihub22266oqcxt.onion/10.1158/0008-5472.CAN-15-2974 C5033673!5033673!27262172     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Res 2016 ; 76 (14): 4183-91 Nephropedia Template TP {{tp|p=27262172|t=2016. A novel chemotherapeutic agent to treat tumors with DNA mismatch repair deficiencies |pdf=|usr=}}{{27262172}} gab.com Text A novel chemotherapeutic agent to treat tumors with DNA mismatch repair deficiencies JO: Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=27262172 #FOAvip Impairing the division of cancer cells with genotoxic small molecules has been a primary goal to develop chemotherapeutic agents. However, DNA mismatch repair (MMR)-deficient cancer cells, are resistant to most conventional chemotherapeutic agents. Here we have identified baicalein as a small molecule that selectively kills MutS?-deficient cancer cells. Baicalein binds preferentially to mismatched DNA and induces a DNA damage response in a mismatch repair-dependent manner. In MutS?-proficient cells, baicalein binds to MutS? to dissociate CHK2 from MutS? leading to S phase arrest and cell survival. In contrast, continued replication in the presence of baicalein in MutS?-deficient cells results in a high number of DNA double-strand breaks and ultimately leads to apoptosis. Consistently, baicalein specifically shrinks MutS?-deficient xenograft tumors and inhibits the growth of AOM-DSS-induced colon tumors in colon-specific MSH2 knockout mice. Collectively, baicalein offers the potential of an improved treatment option for patients with tumors with a DNA MMR deficiency. Twit Text FOAVip A novel chemotherapeutic agent to treat tumors with DNA mismatch repair deficiencies ????Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=27262172 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27262172 #FOAvip English Wikipedia <ref>{{Cite pmid|27262172}}</ref> A novel chemotherapeutic agent to treat tumors with DNA mismatch repair deficiencies #MMPMID27262172 Zhang Y; Fox JT; Park YU; Elliott G; Rai G; Cai M; Sakamuru S; Huang R; Xia M; Lee K; Jeon MH; Mathew BP; Park HD; Edelmann W; Park CY; Hong SY; Maloney D; Myung K Cancer Res 2016[Jul]; 76 (14): 4183-91 PMID27262172show ga Impairing the division of cancer cells with genotoxic small molecules has been a primary goal to develop chemotherapeutic agents. However, DNA mismatch repair (MMR)-deficient cancer cells, are resistant to most conventional chemotherapeutic agents. Here we have identified baicalein as a small molecule that selectively kills MutS?-deficient cancer cells. Baicalein binds preferentially to mismatched DNA and induces a DNA damage response in a mismatch repair-dependent manner. In MutS?-proficient cells, baicalein binds to MutS? to dissociate CHK2 from MutS? leading to S phase arrest and cell survival. In contrast, continued replication in the presence of baicalein in MutS?-deficient cells results in a high number of DNA double-strand breaks and ultimately leads to apoptosis. Consistently, baicalein specifically shrinks MutS?-deficient xenograft tumors and inhibits the growth of AOM-DSS-induced colon tumors in colon-specific MSH2 knockout mice. Collectively, baicalein offers the potential of an improved treatment option for patients with tumors with a DNA MMR deficiency. äA novel chemotherapeutic agent to treat tumors with DNA mismatch repai(epmc).pdf DeepDyve Pubget Overpricing